News about BioPorto

NGAL Biomarker
Detected 2-3 days before creatinine rises

Until now, assessing risk of AKI (Acute Kidney Injury) in critically ill patients has relied on changes in serum creatinine and urine output, physiologic endpoints that are delayed, non-specific, and impacted by extrarenal factors such as nutritional status and muscle mass.
The NGAL biomarker rises rapidly in response to kidney injury, preceding changes in creatinine by as much as 2 to 3 days.
By identifying patients at risk of AKI early, clinicians can take more appropriate action to manage fluid levels, avoid nephrotoxic agents, and potentially prevent permanent kidney damage.

Highly reproducible working solutions, ready-to-use calibrators, and pre-coated 96-well ELISA plates.

NGAL – a renal tubular injury biomarker 
BioPorto offers NGAL ELISA kits for the following species: mouse, rat, pig, dog, monkey, and human. These kits can help researchers and scientists investigating nephrotoxicity and other sources of tubular injury to connect preclinical and clinical research by offering species-specific assays from mouse to man.
The use of NGAL in phase 1 clinical trials is supported by FDA and EMA.

Info BioPorto

Diagnostic tests and antibodies for clinical and research studies.

BioPorto is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Their pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury and Mannan-Binding Lectin (MBL) ELISA Kit for IVD Key test in the assesment of Primary Immunodeficiency.

For more information:
Currently there are no products of the brand BioPorto in our catalog.